# Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

> **NCT04336241** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Replimune, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** RP2
- **BIOLOGICAL:** nivolumab

## Key facts

- **NCT ID:** NCT04336241
- **Lead sponsor:** Replimune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-17
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04336241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04336241, "Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04336241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*